Trinidad CH Vancomycin (Vanc), Trinidad CH Drug 3 Calibrator (DRUG3 CAL)

K160202 · Siemens Healthcare Diagnostics, Inc. · LEH · Apr 27, 2016 · Clinical Toxicology

Device Facts

• Record ID: K160202
• Device Name: Trinidad CH Vancomycin (Vanc), Trinidad CH Drug 3 Calibrator (DRUG3 CAL)
• Applicant: Siemens Healthcare Diagnostics, Inc.
• Product Code: LEH · Clinical Toxicology
• Decision Date: Apr 27, 2016
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3950
• Device Class: Class 2

Indications for Use

The Trinidad CH Vancomycin (Vanc) assay is for in vitro diagnostic use in the quantitative measurement of vancomycin in human serum or plasma on the Trinidad CH System. Vanc test results may be used in the diagnosis and treatment of vancomycin overdose and in monitoring levels of vancomycin to ensure appropriate therapy. The Trinidad CH Drug 3 Calibrator (DRUG3 CAL) is intended for in vitro diagnostic use in the calibration of Vancomycin (Vanc) on the Trinidad CH System.

Device Story

The Trinidad CH Vancomycin assay is an in vitro diagnostic test for human serum or plasma. It utilizes a homogeneous particle-enhanced turbidimetric inhibition immunoassay (PETINIA) technique. The device uses a synthetic particle-vancomycin conjugate and monoclonal vancomycin-specific antibody. Vancomycin in the patient sample competes with the particle-bound vancomycin for antibody binding, decreasing the rate of particle aggregation. The system measures the aggregation rate via bichromatic turbidimetric readings at 545 nm and 694 nm. The rate is inversely proportional to the vancomycin concentration. The assay is performed on the Trinidad CH System in a clinical laboratory setting by trained technicians. Results are provided to physicians to guide vancomycin dosing and monitor for potential overdose. The device includes a 5-level bovine serum-based calibrator (DRUG3 CAL) to ensure measurement accuracy.

Clinical Evidence

No clinical studies were performed. Evidence consists of analytical performance testing: precision (N=80 per sample), linearity (r=1.02), limit of detection/quantitation, and interference testing. Method comparison with the predicate device using 100 patient samples yielded a Passing Bablok regression of y = 1.04x - 1.04 (r=0.997).

Technological Characteristics

Turbidimetric immunoassay using mouse monoclonal antibody and synthetic particle-vancomycin conjugate. Bichromatic optical detection at 545 nm and 694 nm. Calibrators are bovine serum-based. System is a clinical chemistry analyzer. Performance validated per CLSI guidelines EP5-A3, EP6-A, EP17-A, EP7-A2, and EP9-A2.

Indications for Use

Indicated for quantitative measurement of vancomycin in human serum or plasma for patients requiring vancomycin monitoring or suspected of overdose. No specific age or gender contraindications provided.

Regulatory Classification

Identification

A vancomycin test system is a device intended to measure vancomycin, an antibiotic drug, in serum. Measurements obtained by this device are used in the diagnosis and treatment of vancomycin overdose and in monitoring the level of vancomycin to ensure appropriate therapy.

Predicate Devices

• Vancomycin Flex Reagent Cartridge (k963267)
• Dimension Drug Calibrator II (k033809)

Submission Summary (Full Text)

{0}

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION MEMORANDUM
ASSAY ONLY TEMPLATE

A. 510(k) Number:
k160202

B. Purpose for Submission:
Addition of a turbidimetric Vancomycin assay to the Trinidad CH System instrument

C. Measurand:
Vancomycin

D. Type of Test:
Quantitative Immunoassay, turbidimetric

E. Applicant:
Siemens Healthcare Diagnostics Inc.

F. Proprietary and Established Names:
Trinidad CH Vancomycin (Vanc) Assay
Trinidad CH Drug 3 Calibrator (DRUG3 CAL)

G. Regulatory Information:
1. Regulation section:
21 CFR 862.3950; Vancomycin test system
21 CFR 862.3200; Clinical Toxicology Calibrator
2. Classification:
Class II
3. Product code:
LEH, DLJ

{1}

4. Panel:
Toxicology (91)

H. Intended Use:

1. Intended use(s):
See Indications for Use below

2. Indication(s) for use:
The Trinidad CH Vancomycin (Vanc) assay is for in vitro diagnostic use in the quantitative measurement of vancomycin in human serum or plasma on the Trinidad CH System. Vanc test results may be used in the diagnosis and treatment of vancomycin overdose and in monitoring levels of vancomycin to ensure appropriate therapy.

The Trinidad CH Drug 3 Calibrator (DRUG3 CAL) is intended for in vitro diagnostic use in the calibration of Vancomycin (Vanc) on the Trinidad CH System.

3. Special conditions for use statement(s):
For in vitro diagnostic use only
For professional use only

4. Special instrument requirements:
Trinidad CH System

I. Device Description:

The Trinidad CH Vancomycin (Vanc) assay is a turbidimetric assay previously cleared for use on the dimension clinical chemistry system in K963267. The Trinidad CH System instrument was previously cleared in k151767, but has not previously been cleared for use with any turbidimetric assays.

The Trinidad CH Vancomycin (Vanc) assay is a two reagent assay provided in reagent packs each contains two reagent wells. The contents of the reagent packs are the following:
- Vancomycin P1: Well 1, Particle Reagent 2.5 g/L; Well 2, Buffer 25.7 mM
- Vancomycin P2: Well 1: Antibody 0.034 g/L; Well 2, empty.

The Trinidad CH Drug 3 Calibrator is a five level product. The saleable device is packaged with 2 vials of each level in a box. The vials are amber borosilicate glass with

{2}

resealable polypropylene caps. The fill volume target is 5.1 mL.

Controls are not provided. The sponsor recommends the use of commercially available controls for the assay.

## J. Substantial Equivalence Information:

1. Predicate device name(s):

Dimension® VANC Flex® reagent Cartridge
Dimension Drug Calibrator II

2. Predicate 510(k) number(s):

k963267; k033809

3. Comparison with predicate:

| Item | Candidate Device
Trinidad CH Vancomycin
(VANC) | Predicate Device
Dimension® VANC
Flex®
reagent Cartridge
(k963267) |
| --- | --- | --- |
| Similarities | | |
| Intended Use | For in vitro diagnostic use
in the quantitative measurement
of Vancomycin in human serum
or plasma. | Same |
| Methodology | Homogeneous particle enhanced
turbidimetric inhibition
immunoassay (PETINIA)
technique. | Same |
| Assay composition | Mouse monoclonal antibody,
Particle reagent,
buffer | Same |
| Specimen type | Serum and Lithium-Heparin
plasma | Same |
| Traceability | Traceable to USP reference
standards | Same |
| Differences | | |
| Measuring range | 3.0–50.0 μg/mL | 0.0 – 50.0 μg/mL |
| Instrumentation | Trinidad CH System | Cleared to be used on
dimension clinical
chemistry system |
| Calibrators | Trinidad CH Drug 3
Calibrator | Dimension Drug
Calibrator II |

{3}

| Item | Candidate Device Trinidad CH Drug 3 Calibrator (DRUG3 CAL) | Predicate Device Dimension Drug Calibrator II (k033809) |
| --- | --- | --- |
| Similarities | | |
| Intended Use | For Vancomycin assay calibration | For calibration of multiple drug assays, including vancomycin |
| Calibrator Matrix: | Bovine Serum Base | Same |
| Levels | 5 | Same |
| Target Values | 1.0, 6.6, 12.5, 25.0, 52.5 μg/mL | Same |
| Differences | | |
| Drugs | Vancomycin only | Multi-drug calibrators including Vancomycin |

# K. Standard/Guidance Document Referenced (if applicable):

- CLSI EP5-A3: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline- Third Edition
- CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline.
- CLSI EP17-A: Protocol for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline.
- CLSI EP7-A2: Interference Testing in Clinical Chemistry: Approved Guideline-Second Edition
- CLSI EP9-A2: Method Comparison and Bias Estimation Using Patient Samples: Approved Guideline- Second Edition

# L. Test Principle:

The Trinidad CH Vancomycin (Vanc) assay is based on a homogeneous particle enhanced turbidimetric inhibition immunoassay (PETINIA) technique which uses a synthetic particle-vancomycin conjugate (PR) and monoclonal vancomycin specific antibody (Ab). Vancomycin present in the sample competes with vancomycin on the particles for available antibody, thereby decreasing the rate of aggregation. Hence, the rate of aggregation is inversely proportional to the concentration of vancomycin in the sample. The rate of aggregation is measured using bichromatic turbidimetric readings at $545~\mathrm{nm}$ and $694~\mathrm{nm}$ .

# M. Performance Characteristics (if/when applicable):

# 1. Analytical performance:

# a. Precision/Reproducibility:

Precision (within-run precision) and intermediate precision (between-day precision) were assessed in accordance with CLSI Guideline EP5-A3 using

{4}

commercial quality control material (serum based), or pooled serum and plasma samples at five different Vancomycin levels. Samples were run in duplicate, twice per day, for 20 days, on a single analyzer using 1 lot of reagent.

| Sample | N | Mean (μg/mL) | Within-Run Precision | | Between-Day Precision | |
| --- | --- | --- | --- | --- | --- | --- |
| | | | SD (μg/mL) | CV(%) | SD (μg/mL) | CV(%) |
| Serum QC | 80 | 6.4 | 0.16 | 2.6 | 0.18 | 2.7 |
| Serum | 80 | 11.2 | 0.20 | 1.8 | 0.23 | 2.0 |
| Serum QC | 80 | 17.5 | 0.28 | 1.6 | 0.35 | 2.0 |
| Serum | 80 | 32.7 | 0.46 | 1.4 | 0.67 | 2.0 |
| Plasma | 80 | 45.8 | 0.78 | 1.7 | 0.83 | 1.8 |

b. Linearity/assay reportable range:

Linearity was evaluated with 10 samples which spanned the assay measuring interval (0.9, 3.0, 7.2, 13.5, 19.7, 26.0, 32.3, 38.6, 44.8, 51.1 μg/mL). Each was prepared by mixing high and low concentration samples across the measurement interval as described in CLSI EP06-A. The high sample was prepared by spiking native serum with purified Vancomycin Hydrochloride. The low sample was normal human serum with low level of Vancomycin. Six replicates were measured for each sample. The mean of these replicates was used for the regression analysis.

The result of the liner regression is: $y = 1.009x - 0.16545$ , $r = 1.02$

The results support the claimed measuring range of $3.0 - 50~\mu \mathrm{g / mL}$

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability

The Trinidad CH Drug 3 Calibrator is traceable to USP Vancomycin.

Calibrator Stability

Protocols and acceptance criteria for the stability studies were reviewed and found acceptable. The real-time study results support open-vial/on board stability of 15 days at $2 - 8^{\circ}\mathrm{C}$ . Real time closed-vial stability studies are ongoing to support a shelf-life of 12 months or longer at $2 - 8^{\circ}\mathrm{C}$ .

Expected Values

Value assignment for Trinidad CH Drug 3 Calibrators will be conducted as for the predicate device cleared in K033809.

{5}

d. Detection limits:

Analytical sensitivities were determined following EP17-A2 using the nonparametric approach.

To determine LoB, 4 analyte-free samples (bovine serum base) were tested in replicate of 5 per run, with one run per day for 3 days, for a total of 60 measurements using each reagent lot (3 reagent lots were tested). The sponsor defined LoB as the concentration below which analyte-free samples could be found with a probability of 95%.

To determine LoD, 4 serum samples with low-analyte concentrations (0.1-0.3 µg/mL) were tested in replicate of 5 per run, with one run per day for 3 days, for a total of 60 measurements using each reagent lot (3 reagent lots were tested). The sponsor defined LoD as the lowest analyte concentration which could be detected, with a value above the LoB, with a probability of 95%.

To verify the claimed LoQ of 3.0 µg/mL, 4 serum samples with Vacomycine concentration of 2.5 µg/mL were tested using three reagent lots for three days, on one instrument for a total of 180 measurements. The acceptance criteria for LoQ were that the total error at the tested analyte concentration should be less than 20%.

The results are summarized in the table below and support the claimed LoB, LoD and LoQ.

| | LoB (µg/mL) | LoD (µg/mL) | LoQ (µg/mL) |
| --- | --- | --- | --- |
| Lot 1 | 0.1 | 0.16 | 2.51 |
| Lot 2 | -0.1 | 0.17 | 2.37 |
| Lot 3 | 0.1 | 0.19 | 2.77 |
| Claimed | 0.1 | 0.2 | 3.0 |

e. Analytical specificity:

Interference

The sponsor tested the effects of common endogenous substances and therapeutic compounds using human serum pools at both low (10µg/mL) and high (40µg/mL) Vancomycin levels. The % difference between the test sample and the control sample was calculated. The sponsor defined no significant interference as within a ±10% difference relative to the control sample.

No interference was detected for hemolysis, icterus and lipemia at the following concentrations: Hemoglobin 600 mg/dL, Conjugated Bilirubin 20 mg/dL, Unconjugated Bilirubin 20 mg/dL, Lipemia (Intralipid) 1000 mg/dL.

No interference was detected from the following therapeutic and endogenous substances at the indicated concentrations:

{6}

| Substance | Highest Concentration at which no significant interference was detected | |
| --- | --- | --- |
| Acetaminophen | 20 | mg/dL |
| Acetylsalicylic Acid | 50 | mg/dL |
| Amikacin | 100 | μg/mL |
| Amobarbital | 10 | mg/dL |
| Ampicillin | 5 | mg/dL |
| Ascorbic Acid | 3 | mg/dL |
| Caffeine | 10 | mg/dL |
| Carbamazepine | 12 | mg/dL |
| Cefazolin | 500 | μg/mL |
| Cefotaxime | 1000 | μg/mL |
| Chloramphenicol | 100 | μg/mL |
| Chlordiazepoxide | 2 | mg/dL |
| Chlorpromazine | 5 | mg/dL |
| Cimetidine | 10 | mg/dL |
| Clindamycin | 300 | μg/dL |
| Codeine | 10 | mg/dL |
| Creatinine | 30 | mg/dL |
| Dextran 40 | 6000 | mg/dL |
| Dextran 70 | 2500 | mg/dL |
| Diazepam | 4 | mg/dL |
| Digoxin | 5 | ng/dL |
| Erythromycin | 20 | mg/dL |
| Ethanol | 350 | mg/dL |
| Ethosuximide | 30 | mg/dL |
| Furosemide | 2 | mg/dL |
| Fusidic Acid | 500 | μg/mL |
| Gentamicin | 12 | mg/dL |
| Heparin (Porcine) | 8000 | U/L |
| Ibuprofen | 40 | mg/dL |
| Lidocaine | 6 | mg/dL |
| Lithium | 3.5 | mg/dL |

{7}

8

| Methicillin | 500 | μg/mL |
| --- | --- | --- |
| Netilmicin | 500 | μg/mL |
| Nicotine | 2 | mg/dL |
| Penicillin V | 80 | mg/dL |
| Pentobarbital | 10 | mg/dL |
| Phenobarbital | 15 | mg/dL |
| Phenytoin | 10 | mg/dL |
| Primidone | 10 | mg/dL |
| Propoxyphene | 0.4 | mg/dL |
| Protein-Albumin | 12 | g/dL |
| Protein-IgG | 5 | g/dL |
| Protein–Total | 12 | g/dL |
| Rheumatoid Factor | 1465 | U/mL |
| Rifampin | 50 | μg/mL |
| Salicylic Acid | 50 | mg/dL |
| Secobarbital | 5 | mg/dL |
| Sodium Fluoride | 1 | mg/dL |
| Sulfamethoxazole | 25 | μg/mL |
| Theophylline | 25 | mg/dL |
| Tobramycin | 100 | μg/mL |
| Trimethoprim | 25 | μg/mL |
| Urea | 500 | mg/dL |
| Uric Acid | 20 | mg/dL |
| Valproic Acid | 50 | mg/dL |

## Cross Reactivity

Vancomycin crystalline degradation product (CDP-1) was tested for cross-reactivity at 0 and 10 μg/mL of vancomycin following CLSI document EP07-A2. The results are summarized in the below table.

| Cross reactant | Test Concentration | Cross-reactivity | |
| --- | --- | --- | --- |
| | μg/mL | 0.0 μg/mL Vancomycin | 10 μg/mL Vancomycin |
| CDP-1 | 20 | 21.0% | 19.1% |
| CDP-1 | 15 | 20.8% | 18.9% |
| CDP-1 | 10 | 20.5% | 19.5% |
| CDP-1 | 5 | 22.0% | 19.0% |

{8}

In the labeling, the sponsor states:

A number of substances cause physiological changes in serum or plasma analyte concentrations. A comprehensive discussion of possible interfering substances, their serum or plasma concentrations, and their possible physiological involvements is beyond the scope of this document. Consult the listed reference for specific details on known potential interfering substances.⁶

As with any chemical reaction, you must be alert to the possible effect on results of unknown interferences from medications or endogenous substances. The laboratory and physician must evaluate all patient results in light of the total clinical status of the patient.

Vancomycin crystalline degradation product (CDP-1) at 20 µg/mL CDP-1 demonstrates cross-reactivity at 0 and 10 µg/mL Vanc of 21.0% and 19.1% respectively.

f. Assay cut-off:
Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:
The sponsor tested 100 human serum samples (98 were native, 2 were altered) from patients taking Vancomycin, ranging in concentration from 4.4 to 48.1 µg/mL. The samples were tested in singlicate using the candidate and predicate device and analyzed using Passing Bablok regression which yielded the following regression equation: y = 1.04x -1.04, r = 0.997.

b. Matrix comparison:
A matrix comparison study between serum and Lithium-Heparin plasma was performed using 60 matched samples with Vancomycin concentrations from 4.0 to 43.3 µg/mL. The equation produced from linear regression analysis was:
y = 1.00x + 0.49, r = 0.990

3. Clinical studies:

a. Clinical Sensitivity:
Not applicable.

b. Clinical specificity:
Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.

4. Clinical cut-off:

{9}

Not applicable.

5. Expected values/Reference range:

In the labeling, the sponsor states:

The therapeutic intervals are cited from the literature $^{1,2}$:

There is great disparity in vancomycin therapeutic intervals, especially with peak therapeutic intervals. Factors that might affect peak therapeutic ranges include dosage regimen and timing of sample collection.

Vancomycin levels in renal dialysis patients, burn patients and intravenous drug abusers should be closely monitored.

Peak Intervals: Samples from adult volunteers drawn two hours after the completion of a 60 minute infusion of vancomycin ranged from $18 - 26\ \mu\mathrm{g/mL}$. Samples drawn one hour after the completion of a 60 minute vancomycin infusion ranged from $25 - 40\ \mu\mathrm{g/mL}$. Samples drawn 30 minutes after the completion of a 60 minute infusion of vancomycin ranged from $30 - 40\ \mu\mathrm{g/mL}$.

Trough Intervals: Samples should be drawn just before the next dose. A trough interval of $5 - 10\ \mu\mathrm{g/mL}$ (3.5–6.9 $\mu\mathrm{mol/L}$) is generally considered to be effective; however, therapeutic levels should be established based on individual patient differences, clinical assessment, and bacterial susceptibility.

As with all in vitro diagnostic assays, each laboratory should determine its own reference intervals for the diagnostic evaluation of patient results. Consider these values as a guideline only.

1. Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Biology, Fourth Edition, Elsevier Saunders, St. Louis, MO; pp. 1253 (clinical significance), pp. 2315 (reference values).
2. Finn AL, Taylor WJ. Individualizing Drug Therapy, Practical Applications of Drug Monitoring. New York: Gross, Townsend, Frank, Inc., 1981: 87-108.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.